Grove Biopharma Closes $30 Million Series A Financing to Advance Bionic Biologics™, a New Therapeutic Modality
– Proprietary Platform Integrates Principles of Biologic and Synthetic Design, Producing Drug Candidates that Selectively Disrupt or Degrade Previously Intractable Intracellular Targets – – Experienced, Multidisciplinary Team Well-Positioned to Advance Lead Programs to the Clinic…